
Supplements and Featured Publications
- Examining the Clinical and Economic Burden of OFF Periods in Parkinson Disease
- Volume 26
- Issue 12
Participating Faculty
FACULTY
Caroline M. Tanner, MD, PhD
Professor, Neurology
University of California, San Francisco
Director, PADRECC
San Francisco Veterans Affairs Health Care System
San Francisco, California
Iresha Abeynayake, MPH
Associate Director of Medical Affairs and Health Outcomes Research
Acorda Therapeutics
Ardsley, New York
FACULTY DISCLOSURES
Caroline M. Tanner, MD, PhD
RESEARCH GRANT SUPPORT
Michael J. Fox Foundation; Parkinson’s Foundation; US Department of Defense; BioElectron; Roche/Genentech; Biogen Idec; National Institutes of Health
HONORARIA
Voyager Therapeutics; Intec Pharma; Biogen; Cadent Therapeutics; Neurocrine Biosciences; Adamas Therapeutics; Grey Matter; Acorda Therapeutics; Acadia; Amneal; CNS Ratings
Iresha Abeynayake, MPH
EMPLOYMENT
Acorda Therapeutics
STOCK OWNERSHIP
Acorda Therapeutics
Articles in this issue
about 5 years ago
Exploring the Clinical Burden of OFF Periods in Parkinson Diseaseabout 5 years ago
The Economic Impact of OFF Periods in Parkinson DiseaseNewsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.